Advanced search
Publication Cover
Leukemia & Lymphoma Volume 56, 2015 - Issue 7
Submit an article Journal homepage
409
Views
18
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era

Chieh-Sheng LuDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan;Department of Internal Medicine, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan
,
Jia-Hong ChenDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
,
Tzu-Chuan HuangDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
,
Yi-Ying WuDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
,
Ping-Ying ChangDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
,
Ming-Shen DaiDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
,
Yeu-Chin ChenDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
&
Ching-Liang HoDivision of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, TaiwanCorrespondence[email protected]
 show all
Pages 2047-2055 | Received 22 May 2014, Accepted 27 Oct 2014, Published online: 14 Jan 2015

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Jinrong Zhao, Wei Zhang & Daobin Zhou. (2022) Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis. Hematology 27:1, pages 757-764.
Read now
Hiromichi Takahashi, Katsuhiro Miura, Masaru Nakagawa, Masahiko Sugitani, Yusuke Amano, Daisuke Kurita, Masashi Sakagami, Shimon Ohtake, Yoshihito Uchino, Hitomi Kodaira, Noriyoshi Iriyama, Sumiko Kobayashi, Atsuko Hojo, Yujin Kobayashi, Yukio Hirabayashi, Machiko Kusuda, Yoshihiro Hatta, Tomohiro Nakayama & Masami Takei. (2016) Negative impact of concurrent overexpression of MYC and BCL2 in patients with advanced diffuse large B-cell lymphoma treated with dose-intensified immunochemotherapy. Leukemia & Lymphoma 57:12, pages 2784-2790.
Read now

Articles from other publishers (16)

Leandro Venturutti, Martin A. Rivas, Benedikt W. Pelzer, Ruth Flümann, Julia Hansen, Ioannis Karagiannidis, Min Xia, Dylan R. McNally, Yusuke Isshiki, Andrew Lytle, Matt Teater, Christopher R. Chin, Cem Meydan, Gero Knittel, Edd Ricker, Christopher E. Mason, Xiaofei Ye, Qiang Pan-Hammarström, Christian Steidl, David W. Scott, Hans Christian Reinhardt, Alessandra B. Pernis, Wendy Béguelin & Ari M. Melnick. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer Discovery 13:1, pages 216-243.
Crossref
Si‐Yuan Chen, Meng‐Meng Ji, Peng‐Peng Xu & Wei‐Li Zhao. (2022) Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis. Aging and Cancer 3:3-4, pages 133-146.
Crossref
Zhiqiang Song, Lili Xu, Gusheng Tang, Lei Gao, Libing Wang, Xiong Ni, Li Chen, Jie Chen, Tao Wang, Dongge Feng, Xuejun Yu, Jianmin Yang & Yang Wang. (2022) Prognostic differences of refractory/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era. Clinica Chimica Acta 532, pages 72-78.
Crossref
Antonello Sica, Mario Santagata, Caterina Sagnelli, Piero Rambaldi, Renato Franco, Massimiliano Creta, Paola Vitiello, Stefano Caccavale, Vincenzo Tammaro, Evangelista Sagnelli & Andrea Ronchi. (2021) Primary Extra-Nodal DLBCL of Glands: Our Experiences outside Guidelines of Treatment. Healthcare 9:3, pages 286.
Crossref
Tiago Rabadão, Leonor Naia, Filipa Ferreira, Mariana Teixeira, Marcelo Aveiro, Margarida Eulálio & Fernando Silva. (2021) Not Always (and Only) Heart Failure—A Case Report of Primary Pleural Lymphoma in an Elderly Patient. Clinics and Practice 11:1, pages 32-36.
Crossref
ChandranK Nair, AnjuR Kurup, A Manuprasad, PraveenKumar Shenoy & Vineetha Raghavan. (2021) Pattern of extranodal involvement and its impact on survival in diffuse large B-cell lymphoma from a tertiary cancer center in rural India. Journal of Cancer Research and Therapeutics 17:4, pages 938.
Crossref
Xuejiao Yin, Aoshuang Xu, Fengjuan Fan, Zhenli Huang, Qianwen Cheng, Lu Zhang, Chunyan Sun & Yu Hu. (2019) Incidence and Mortality Trends and Risk Prediction Nomogram for Extranodal Diffuse Large B-Cell Lymphoma: An Analysis of the Surveillance, Epidemiology, and End Results Database. Frontiers in Oncology 9.
Crossref
Doh Young Lee, Karam Kang, Hwaejoon Jung, Young Min Park, Jae-Gu Cho, Seung-Kuk Baek, Soon-Young Kwon, Kwang-Yoon Jung & Jeong-Soo Woo. (2019) Extranodal involvement of diffuse large B-cell lymphoma in the head and neck: An indicator of good prognosis. Auris Nasus Larynx 46:1, pages 114-121.
Crossref
José M. Porcel, Irene Cuadrat, Tomás García-Cerecedo, Marina Pardina & Silvia Bielsa. (2018) Pleural Effusions in Diffuse Large B-Cell Lymphoma: Clinical and Prognostic Significance. Lung 197:1, pages 47-51.
Crossref
Thomas A. Ollila & Adam J. Olszewski. (2018) Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence. Current Treatment Options in Oncology 19:8.
Crossref
Jeffrey W. Craig, Michael J. Mina, Jennifer L. Crombie, Ann S. LaCasce, David M. Weinstock, Geraldine S. Pinkus & Olga Pozdnyakova. (2018) Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. PLOS ONE 13:7, pages e0199708.
Crossref
Jorne Biccler, Sandra Eloranta, Peter de Nully Brown, Henrik Frederiksen, Mats Jerkeman, Karin E. Smedby, Martin Bøgsted & Tarec C. El-Galaly. (2018) Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI. Cancer Medicine 7:1, pages 114-122.
Crossref
Junshik Hong, Seok Jin Kim, Myung Hee Chang, Jeong-A Kim, Jae-Yong Kwak, Jin Seok Kim, Dok Hyun Yoon, Won Sik Lee, Young Rok Do, Hye Jin Kang, Hyeon-Seok Eom, Yong Park, Jong-Ho Won, Yeung-Chul Mun, Hyo Jung Kim, Jung Hye Kwon, Jee Hyun Kong, Sung Yong Oh, Sunah Lee, Sung Hwa Bae, Deok-Hwan Yang, Hyun Jung Jun, Ho Sup Lee, Hwan Jung Yun, Soon Il Lee, Min Kyoung Kim, Jun Ho Yi, Jae Hoon Lee, Won Seog Kim & Cheolwon Suh. (2017) Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma. Oncotarget 8:54, pages 92171-92182.
Crossref
Carlos Montalbán, Antonio Díaz-López, Ivan Dlouhy, Jordina Rovira, Armando Lopez-Guillermo, Sara Alonso, Alejandro Martín, Juan M. Sancho, Olga García, Jose M. Sánchez, Mario Rodríguez, Silvana Novelli, Antonio Salar, Antonio Gutiérrez, Maria J. Rodríguez-Salazar, Mariana Bastos, Juan F. Domínguez, Rubén Fernández, Sonia Gonzalez de Villambrosia, José A. Queizan, Raul Córdoba, Raquel de Oña, Andrés López-Hernandez, Julian M. Freue, Heidys Garrote, Lourdes López, Ana M. Martin-Moreno, Jose Rodriguez, Víctor Abraira & Juan F. García. (2017) Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β 2 -microglobulin yields a more accurate GELTAMO-IPI . British Journal of Haematology 176:6, pages 918-928.
Crossref
Hee Sang Hwang, Dok Hyun Yoon, Cheolwon Suh & Jooryung Huh. (2016) A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy. Annals of Hematology 95:8, pages 1249-1258.
Crossref
T Kobayashi, J Kuroda, I Yokota, K Tanba, T Fujino, S Kuwahara, R Isa, J Yamaguchi, E Kawata, T Akaogi, H Uchiyama, H Kaneko, N Uoshima, Y Kobayashi, S Teramukai & M Taniwaki. (2016) The Kyoto Prognostic Index for patients with diffuse large B-cell lymphoma in the rituximab era. Blood Cancer Journal 6:1, pages e383-e383.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.